Clinical application of gene expression analysis in patients with insect venom allergy

Clinical application of gene expression analysis in patients with insect venom allergy - Gene expression analysis in insect venom allergy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33607

Enrollment

Registered

2009-02-20

Start date

2009-01-20

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hymenoptera allergy insect venom allergy

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria are the diagnosis of insect venom allergy based on medical history (grade IV according to Mueller before VIT), positive skin tests or sIgE and exclusion of mastocytosis

Exclusion criteria

Exclusion criteria: Exclusion criteria are lack of consent, pregnancy, severe chronic or/and malignant disease, mastocytosis

Design outcomes

Primary

Measure	Time frame
The main parameter of the study is the gene expression profile which may predict the long term effect of venom immunotherapy.	—

Secondary

Measure	Time frame
1. The secondary parameter is the gene expression profile which will be specific for patients with the highest risk at a systemic reaction at a resting * before insect venom immunotherapy? 2. The tertiary parameter is the gene expression profile specific for patients with the lowest risk of the systemic reaction to insect sting at the end of maintenance phase of VIT?	—

Countries

Netherlands

Outcome results